VKORC1 haplotypes and their impact on the inter-individual and inter-ethnical variability of oral anticoagulation

Summary

In order to elucidate the role of VCORC1 sequence variants in warfarin sensitivity, we established a complete SNP map of the VKORC1 gene locus in 200 blood donors from Western Germany. Nearly all of the genetic variability of the VKORC1 gene in Europeans is reflected by three main haplotypes. Recently described polymorphisms associated with low warfarin dose requirement (dbSNP:rs9934438; dbSNP:rs17878363) were found in complete linkage disequilibrium with the VKORC1*2 haplotype. In two patient cohorts of European origin with either increased coumarin sensitivity (n=14) or partial coumarin resistance (n=36) the VKORC1*2 frequency varied highly significant between the two groups and also when compared to 200 blood donor controls (coumarin sensitive 96%, coumarin resistant 7%, controls 42%) thus demonstrating a strong association between these two phenotypes and the VKORC1 haplotype (p = 1.6 x 10⁻⁸ for coumarin sensitive and p = 1.9 x 10⁻⁸ for coumarin resistant). Analysis of database derived VKORC1 genotypes of African Americans and Chinese revealed that haplotype frequencies in these populations differ significantly from the European sample (for VKORC1*2: Europeans 42%, Chinese 95%, African Americans 14%). These observations suggest VKORC1 as principal genetic modulator of the ethnic differences in warfarin response. Since hereditary pharmacodynamic (VKORC1) and pharmacokinetic (CYP2C9) factors account for up to 50% of the inter-individual variability of the warfarin response, these genetic markers may serve as clinically relevant predictors of warfarin dosing in future studies.

Keywords

Vitamin K epoxide reductase - VKORC1 - warfarin - vitamin K - haplotype

• References

• 1 Rost S, Fregin A, Ivaskevicius V. et al. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature 2004; 427: 537-41.
• 2 Li T, Chang CY, Jin DY, Lin P J. et al. Identification of the gene for vitamin K epoxide reductase. Nature 2004; 427: 541-4.
• 3 Wajih N, Sane DC, Hutson S M. et al. Engineering of a recombinant vitamin K-dependent gamma-carboxylation system with enhanced gamma-carboxyglutamic acid forming capacity: evidence for a functional CXXC redox center in the system. J Biol Chem 2005; 280: 10540-7.
• 4 Berkner KL, Runge KW. The physiology of vitamin K nutriture and vitamin K-dependent protein function in atherosclerosis. J Thromb Haemost 2004; 2: 2118-32.
• 5 Harrington DJ, Underwood S, Morse C. et al. Pharmacodynamic resistance to warfarin associated with a Val66Met substitution in vitamin K epoxide reductase complex subunit 1. Thromb Haemost 2005; 93: 23-6.
• 6 Pelz HJ, Rost S, Hünerberg M. et al. The genetic basis of resistance to anticoagulants in rodents. Genetics 2005; 170: 1839-47.
• 7 D’Andrea G, D’Ambrosio RL, Di Perna P. et al. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood 2005; 105: 645-9.
• 8 James AH, Britt RP, Raskino C L. et al. Factors affecting the maintenance dose of warfarin. J Clin Pathol 1992; 45: 704-6.
• 9 Gage BF, Eby C, Milligan P E. et al. Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin. Thromb Haemost 2004; 91: 87-94.
• 10 Gage BF, Fihn SD, White RH. Management and dosing of warfarin therapy. Am J Med 2000; 109: 481-8.
• 11 Ristola P, Pyorala K. Determinants of the response to coumarin anticoagulants in patients with acute myocardial infarction. Acta Med Scand 1972; 192: 183-8.
• 12 Fergusson RJ, Eade OE, Logie A W. et al. A flexible loading dose schedule for warfarin therapy. Scott Med J 1987; 32: 169-71.
• 13 Absher RK, Moore ME, Parker MH. Patient-specific factors predictive of warfarin dosage requirements. Ann Pharmacother 2002; 36: 1512-7.
• 14 Lubetsky A, Dekel-Stern E, Chetrit A. et al. Vitamin K intake and sensitivity to warfarin in patients consuming regular diets. Thromb Haemost 1999; 81: 396-9.
• 15 Cushman M, Booth SL, Possidente C J. et al. The association of vitamin K status with warfarin sensitivity at the onset of treatment. Br J Haematol 2001; 112: 572-7.
• 16 Taube J, Halsall D, Baglin T. Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. Blood 2000; 96: 1816-9.
• 17 Visser LE, van Schaik RH, van Vliet M. et al. The risk of bleeding complications in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon. Thromb Haemost 2004; 92: 61-6.
• 18 Morin S, Bodin L, Loriot M A. et al. Pharmacogenetics of acenocoumarol pharmacodynamics. Clin Pharmacol Ther 2004; 75: 403-14.
• 19 The International. HapMap Project. Nature 2003; 426: 789-96.
• 20 Hosking L, Lumsden S, Lewis K. et al. Detection of genotyping errors by Hardy-Weinberg equilibrium testing. Eur J Hum Genet 2004; 12: 395-9.
• 21 Devlin B, Risch N. A comparison of linkage disequilibrium measures for fine-scale mapping. Genomics 1995; 29: 311-22.
• 22 Zhao JH, Curtis D, Sham PC. Model-free analysis and permutation tests for allelic associations. Hum Hered 2000; 50: 133-9.
• 23 Becker T, Knapp M. A powerful strategy to account for multiple testing in the context of haplotype analysis. Am J Hum Genet 2004; 75: 561-70.
• 24 Bodin L, Verstuyft C, Tregouet D A. et al. Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. Blood 2005; 106: 135-40.
• 25 Yuan HY, Chen JJ, Lee M T. et al. A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. Hum Mol Genet 2005; 14: 1745-51.
• 26 Wadelius M, Chen LY, Downes K. et al. Common VKORC1 and GGCX polymorphisms associated with warfarin dose. Pharmacogenomics J 2005; 5: 262-70.
• 27 Rieder MJ, Reiner AP, Gage B F. et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 2005; 352: 2285-93.
• 28 Hallgren KW, Hommema EL, McNally BA. et al. Carboxylase overexpression effects full carboxylation but poor release and secretion of factor IX: implications for the release of vitamin K-dependent proteins. Biochemistry 2002; 41: 15045-55.
• 29 Gan GG, Teh A, Goh K Y. et al. Racial background is a determinant factor in the maintenance dosage of warfarin. Int J Hematol 2003; 78: 84-6.
• 30 Gan GG, Phipps ME, Ku C S. et al. Genetic polymorphism of the CYP2C9 subfamily of 3 different races in warfarin maintenance dose. Int J Hematol 2004; 80: 295-6.
• 31 Zhao F, Loke C, Rankin S C. et al. Novel CYP2C9 genetic variants in Asian subjects and their influence on maintenance warfarin dose. Clin Pharmacol Ther 2004; 76: 210-9.
• 32 Palareti G, Leali N, Coccheri S. et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet 1996; 348: 423-8.
• 33 Margaglione M, Colaizzo D, D’Andrea G. et al. Genetic modulation of oral anticoagulation with warfarin. Thromb Haemost 2000; 84: 775-8.
• 34 Joffe HV, Xu R, Johnson F B. et al. Warfarin dosing and cytochrome P450 2C9 polymorphisms. Thromb Haemost 2004; 91: 1123-8.
• 35 Daly AK, Aithal GP. Genetic regulation of warfarin metabolism and response. Semin Vasc Med 2003; 3: 231-8.
• 36 Aithal GP, Day CP, Kesteven P J. et al. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 1999; 353: 717-9.
• 37 Higashi MK, Veenstra DL, Kondo L M. et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 2002; 287: 1690-8.
• 38 Tassies D, Freire C, Pijoan J. et al. Pharmacogenetics of acenocoumarol: cytochrome P450 CYP2C9 polymorphisms influence dose requirements and stability of anticoagulation. Haematologica 2002; 87: 1185-91.